Ocular Symptoms of Mucolipidosis

Key Points at a Glance

Highlights of This Disease

Mucolipidosis (ML) is a group of inherited storage disorders caused by defects in the transport or function of lysosomal enzymes. There are four subtypes, ML I to IV, each presenting with different ocular manifestations. In ML I, a cherry-red spot in the macula is seen in all cases. ML II and III cause mild corneal opacities with little impact on vision. ML IV has the most severe ocular involvement, with early corneal opacities followed by progressive retinal dystrophy, cataracts, and strabismus, leading to severe vision loss by the third decade of life. The estimated incidence is 1 in 100,000 to 200,000 people, and all subtypes are inherited in an autosomal recessive pattern.

1. Ocular Manifestations of Mucolipidosis

Mucolipidosis (ML) is a group of inherited lysosomal storage disorders caused by defects in the transport or function of lysosomal enzymes ¹⁾. Glycoproteins, glycolipids, and mucopolysaccharide-like substances accumulate within cells. The estimated incidence is 1 in 100,000 to 200,000 people.

The main subtypes are the following four:

• ML I (Sialidosis): Neuraminidase deficiency due to NEU1 gene mutation ²⁾
• ML II (I-cell disease): GlcNAc-1-phosphotransferase deficiency due to GNPTAB gene mutation ³⁾
• ML III (Pseudo-Hurler polydystrophy): Different mutations in the same gene as ML II ³⁾
• ML IV: Mucolipin-1 (TRPML1) deficiency due to MCOLN1 gene mutation ¹⁾

All are inherited in an autosomal recessive pattern. In Japan, ML II and III are designated as intractable diseases. They present with symptoms similar to mucopolysaccharidosis (MPS), such as coarse facial features, skeletal abnormalities, and intellectual disability, but the key differentiating point is that mucopolysaccharides do not accumulate.

Q What is the difference between mucolipidosis and mucopolysaccharidosis?

A

Mucopolysaccharidosis (MPS) is a group of disorders caused by deficiency of enzymes that break down glycosaminoglycans (mucopolysaccharides), leading to accumulation of mucopolysaccharides. In contrast, mucolipidosis (ML) involves abnormalities in the transport mechanism of lysosomal enzymes themselves, resulting in accumulation of various substrates such as glycolipids and glycoproteins. Although the clinical presentation resembles MPS, they are distinguished by the different substances that accumulate.

2. Main Symptoms and Clinical Findings

Subjective Symptoms

Subjective symptoms vary greatly depending on the subtype.

• ML I: May present as sudden painless vision loss. The degree of loss varies among patients.
• ML II/III: Usually no subjective visual impairment. In ML III, one report found no vision loss over 11 years of follow-up.
• ML IV: Retinal dystrophy progresses within the first 10 years of life, leading to severe vision loss or legal blindness by the 20s.

Clinical Findings (Findings Confirmed by Physician Examination)

ML I (Sialidosis)

Cherry-red spot: Seen in the macula, present in nearly all cases of sialidosis type I^2,4).

Optic atrophy: Thinning of the retinal nerve fiber layer has been reported on SD-OCT, but does not necessarily correlate with visual outcomes⁴⁾.

Nystagmus: May occur.

Lens opacities: Scattered white dot-like opacities that do not affect vision.

ML II (I-cell disease)

Corneal opacity: Mild opacity due to cytoplasmic inclusions in the corneal stroma and epithelium. Usually not associated with visual impairment⁵⁾.

Epicanthal folds: Persistently present.

Mild proptosis: May be observed.

ML III (Pseudo-Hurler Polydystrophy)

Corneal opacity: Mild opacity similar to ML II³⁾

Hyperopic astigmatism: Reported as a rare finding⁶⁾

Retinal/optic nerve abnormalities: Surface wrinkling maculopathy, papilledema, and vascular tortuosity are rarely seen. Electrophysiological tests and color vision are normal⁶⁾

ML IV

Corneal opacity: Epithelial corneal opacity is the earliest ocular symptom appearing in infancy^1,7)

Retinal dystrophy: Develops within the first 10 years of life, accompanied by optic nerve pallor, retinal vascular narrowing, and bone-spicule changes in the retinal pigment epithelium⁷⁾

Cataract: Progressive

Strabismus: Both exotropia and esotropia can occur

Others: Nystagmus, optic atrophy, ptosis

Q Why is corneal transplantation unsuccessful in ML IV?

A

Corneal transplantation has been attempted in ML IV but has not been successful because the donor corneal epithelium is eventually replaced by the abnormal recipient (host) epithelium. The lysosomal transport defect due to MCOLN1 gene mutation persists in the host corneal epithelium, causing similar accumulation abnormalities in the graft.

3. Causes and Risk Factors

All mucolipidoses are caused by mutations in a single gene.

Subtype	Causative Gene	Deficient Enzyme/Protein
ML I	NEU1	Neuraminidase
ML II/III	GNPTAB	GlcNAc-1-phosphotransferase
ML IV	MCOLN1	Mucolipin-1 (TRPML1)

ML I involves a deficiency of neuraminidase, resulting in insufficient removal of sialic acid residues from glycoproteins and oligosaccharides. Sialylated compounds accumulate in lysosomes.

ML II and III involve impaired addition of mannose-6-phosphate (M6P) tags to lysosomal enzymes due to a defect in GlcNAc-1-phosphotransferase. Untagged lysosomal enzymes are secreted outside the cell, leading to enzyme deficiency within lysosomes.

ML IV involves a deficiency of the lysosomal membrane channel TRPML1, impairing lysosomal transport and fusion. Lipids and other substrates accumulate in lysosomes^1,8).

About Genetic Counseling

All mucolipidoses are inherited in an autosomal recessive pattern. If both parents are carriers, the chance of a child being affected is 25%. Genetic counseling is recommended for individuals with a family history.

4. Diagnosis and Testing Methods

Definitive Diagnosis

In all subtypes, genetic testing to confirm biallelic pathogenic variants in the causative gene provides a definitive diagnosis.

Tests for ML I

• Enzyme activity assay: Demonstrates decreased neuraminidase activity in leukocytes or cultured fibroblasts
• Electroencephalography (EEG): May show myoclonic seizure activity
• Brain MRI: May reveal atrophy of the cerebellum, pons, cerebrum, and corpus callosum
• Fundus examination: Confirms cherry-red spots in the macula
• Optical coherence tomography (OCT): Useful for evaluating optic atrophy

Note that increased urinary sialic acid excretion is not a consistent finding.

Tests for ML II and III

• UPLC-MS/MS: Detects free oligosaccharides and glycosaminoglycans such as keratan sulfate in urine
• Serum enzyme activity: Detects elevated lysosomal enzyme activity by tandem mass spectrometry
• Skeletal X-ray: Used to evaluate skeletal abnormalities
• Echocardiography: Assesses valve thickening and ventricular function
• Hearing test: Checks for conductive hearing loss
• Ophthalmic examination: In ML II, ophthalmic evaluation is recommended at 6–12 months of age. Corneal opacity is confirmed by slit-lamp examination. Fundus examination usually shows no retinal abnormalities.
• Refraction under cycloplegia: Used to evaluate hyperopic astigmatism (ML III).
• OCT: Used to detect papilledema and vascular tortuosity (ML III).

Examination for ML IV

• Plasma gastrin: Decreased levels secondary to achlorhydria.
• Complete blood count: May show anemia due to iron malabsorption.
• Brain MRI: Shows corpus callosum hypoplasia (splenium defect/dysplasia), white matter signal abnormalities, and increased ferritin deposition in the thalamus and basal ganglia.
• Electron microscopy: Conjunctival biopsy reveals pleomorphic lysosomal inclusions.
• Strabismus examination: Cover-uncover test detects manifest strabismus, alternate cover test detects latent strabismus, and prism alternate cover test measures the deviation angle.
• Slit-lamp examination: Used to evaluate cataract and corneal opacity. More accurate than direct ophthalmoscopy.
• Multimodal imaging: Combination of SD-OCT and fundus autofluorescence (FAF) provides the most comprehensive assessment of retinal changes ^4,7).

5. Standard Treatment

Currently, there is no curative treatment, and symptomatic therapy is the mainstay.

Treatment for ML I

• Antiepileptic drugs: Valproate, levetiracetam, zonisamide, topiramate, lamotrigine, lacosamide, etc. are used for myoclonic seizures.
• Ophthalmic treatment: Currently, there is no specific ophthalmic treatment.

Treatment for ML II and III

• Occupational therapy: Interactive and stimulating activities to improve alertness, imitation ability, and motivation.
• Gingivectomy: To treat oral pain, infection, and abscess due to gingival hypertrophy.
• Bisphosphonates: Useful for reducing pain and improving mobility in painful osteoporosis (ML III).
• Ophthalmic intervention: Usually not required because corneal opacity and proptosis are mild and do not affect vision. Long-term follow-up alone is sufficient.

Treatment for ML IV

• Iron deficiency anemia: Oral administration of ferrous sulfate.
• Hypotonia and spasticity: Physical therapy, rehabilitation, and botulinum toxin injections.
• Feeding difficulties: Dietary therapy or gastrostomy tube placement.
• Ocular irritation: Topical lubrication with artificial tears, gels, or ointments.
• Strabismus: Surgical correction.
• Corneal transplantation: Has not been successful because donor corneal epithelium is replaced by abnormal host epithelium.

About vision loss

Patients with ML IV gradually lose vision, and there is currently no treatment to reverse this. Early ophthalmologic follow-up and supportive care are important.

Q Has gene therapy for mucolipidosis been put into practical use?

A

AAV (adeno-associated virus)-mediated gene therapy for ML I has shown promising results in mouse models. Co-expression of NEU1 and its chaperone protective protein/cathepsin A restored NEU1 activity and reversed lysosomal accumulation in multiple tissues, including the brain. However, clinical application in humans has not yet been achieved.

6. Pathophysiology and Detailed Pathogenesis

In mucolipidosis, almost all lysosomal enzyme activities are deficient, leading to accumulation of various glycolipids and glycoproteins within lysosomes.

Cellular Mechanisms of Damage

When substrates accumulate in ocular cells, lysosomes swell and disrupt normal cellular structures. This impairs the following key processes:

• Autophagy: Degradation of unnecessary intracellular materials is stalled
• Mitochondrial turnover: Energy production decreases
• Membrane transport: Transport of substances across cell membranes is impaired
• Lysosomal calcium signaling: Intracellular signal transduction is disrupted

These deficiencies cause metabolic and oxidative stress, disrupting normal homeostasis.

Molecular Pathology by Subtype

ML I: Deficiency of neuraminidase leads to accumulation of sialylated compounds in lysosomes. Accumulation in retinal ganglion cells results in a cherry-red spot, where the fovea (lacking ganglion cells) appears red and elevated.

ML II/III: Deficiency of M6P tagging causes lysosomal enzymes to be secreted extracellularly, resulting in enzyme deficiency within lysosomes. Consequently, glycosaminoglycans, lipids, and oligosaccharides accumulate in lysosomes. Deposition in the corneal stroma causes corneal opacity.

ML IV: Deficiency of the TRPML1 channel impairs lipid and protein transport between lysosomes and endosomes. Accumulation occurs in a wide range of ocular tissues, including the corneal epithelium, retinal pigment epithelium, and lens, leading to various ocular symptoms.

7. Latest Research and Future Prospects

Advances in Gene Therapy

AAV-mediated gene therapy for ML I is attracting attention. In mouse models, vectors that simultaneously deliver NEU1 and its chaperone, protective protein/cathepsin A (PPCA), have reported the following outcomes:

• Restoration of NEU1 activity in multiple tissues including the brain
• Reversal of lysosomal accumulation
• Normalization of neuroinflammation

For ML IV, preclinical studies of MCOLN1 gene replacement therapy are also progressing, and intracerebroventricular administration of AAV9 has been shown to improve motor function and myelination and reduce lysosomal accumulation in Mcoln1^−/− mice⁹⁾. Furthermore, a review in the same field (Jezela-Stanek et al. 2020)¹⁰⁾ comprehensively summarizes the pathology and clinical features. Although clinical application in humans has not yet been achieved, it is expected as a future treatment option. For ML II and III, research into novel therapies including gene therapy is also ongoing.

Medical Disclaimer

This article is for informational purposes only and does not substitute for medical advice. Please consult a qualified medical professional for diagnosis and treatment.

References

1. Misko A, Grishchuk Y, Goldin E, Schiffmann R. Mucolipidosis IV. In: GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 2005 Jan 28 [updated 2021 Feb 11]. Bookshelf ID: NBK1214.

2. Tripathy K, Patel BC. Cherry Red Spot. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; [updated 2023 Aug 25]. PMID: 30969663. Bookshelf ID: NBK539841.

3. Leroy JG, Cathey SS, Friez MJ. GNPTAB-Related Disorders. In: GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 2008 Aug 26 [updated 2019 Aug 29]. Bookshelf ID: NBK1828.

4. Daich Varela M, Zein WM, Toro C, Groden C, Johnston J, Huryn LA, d’Azzo A, Tifft CJ, FitzGibbon EJ. A sialidosis type I cohort and a quantitative approach to multimodal ophthalmic imaging of the macular cherry-red spot. Br J Ophthalmol. 2021;105(6):838-843. PMID: 32753397.

5. Libert J, Van Hoof F, Farriaux JP, Toussaint D. Ocular findings in I-cell disease (mucolipidosis type II). Am J Ophthalmol. 1977;83(5):617-628. PMID: 868962.

6. Traboulsi EI, Maumenee IH. Ophthalmologic findings in mucolipidosis III (pseudo-Hurler polydystrophy). Am J Ophthalmol. 1986;102(5):592-597. PMID: 3777077.

7. Smith JA, Chan CC, Goldin E, Schiffmann R. Noninvasive diagnosis and ophthalmic features of mucolipidosis type IV. Ophthalmology. 2002;109(3):588-594. PMID: 11874766.

8. Grishchuk Y, Stember KG, Matsunaga A, Olivares AM, Cruz NM, King VE, Humphrey DM, Wang SL, Muzikansky A, Betensky RA, Thoreson WB, Haider N, Slaugenhaupt SA. Retinal Dystrophy and Optic Nerve Pathology in the Mouse Model of Mucolipidosis IV. Am J Pathol. 2016;186(1):199-209. PMID: 26608452.

9. DeRosa S, Salani M, Smith S, Sangster M, Miller-Browne V, Wassmer S, Xiao R, Vandenberghe L, Slaugenhaupt S, Misko A, Grishchuk Y. MCOLN1 gene therapy corrects neurologic dysfunction in the mouse model of mucolipidosis IV. Hum Mol Genet. 2021;30(10):908-922. PMID: 33822942.

10. Jezela-Stanek A, Ciara E, Stepien KM. Neuropathophysiology, Genetic Profile, and Clinical Manifestation of Mucolipidosis IV—A Review and Case Series. Int J Mol Sci. 2020;21(12):4564. PMID: 32604955; PMCID: PMC7348969.